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CHAPTER 10 
Wasted Money in United States Biomedical and 
Agricultural Animal Research 
Jim Keen 
University of Nebraska-Lincoln, Lincoln, Nebraska, United States 
jekeen918@gmail.com 
1 Background 
To kill an error is as good a service as, and sometimes even better than, 
the establishing of a new truth or fact. 
CHARLES DARWIN, 1879 
Biomedical and agricultural animal research uses millions of experimental 
animals and dozens of animal species each year by choice, precedent, or regu­
latory mandate in basic and applied life science research and toxicity testing of 
drugs, chemicals, and consumer products. Animal research is a large compo­
nent of the international us$270 billion government-subsidized, biomedical 
industrial ecosystem (Chakma et al., 2014). In the United States (us) and pre­
sumably elsewhere, about half of these funds support animal research and 
testing (Institute of Medicine and National Research Council, 2012 ). Each 
year at least 115 million experimental animals (mostly mice and likely a sig­
nificant underestimate) are used worldwide (Akhtar, 2015). The status quo ani­
mal research environment provides "ecosystem services" to a large number of 
inter-dependent "species", including governments, academia, biotechnology, 
agri-food and pharmaceutical industries, and publishers. Losers in this system 
are the conscripted animals (for "labor") and taxpayers (for "capital"). 
Animal research squanders precious public and private monies directly, in­
directly, by opportunity cost, and by unintended negative consequences. There 
is no doubt that biomedical and agricultural animal research have delivered 
societal dividends. Nevertheless, the questionable benefit-cost ratio and the 
unquestionable negative repercussions of animal research are enormous for 
taxpayers, patients, and the public at large. Precise animal research investments 
and attendant waste are impossible to ascertain, in part because the research 
community and the us government obfuscate financial and animal use data. 
However, estimated us tax dollars wasted on animal use in biomedical and 
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agricultural research range, conservatively, from us$5 billion to us$9 billion 
per year. Even though exact monetary and animal use data are unobtainable, 
in this chapter I use the best available, if imprecise, estimates. The estimates 
themselves are arguable, yet the underlying conclusions remain valid. 
2 Biomedical Animal Research 
Animal experiments are of two types: basic ( e.g., investigation of biological 
phenomena and animal models) and applied ( e.g., drug research and devel­
opment (R&D), and toxicity and safety testing). Applied research can also be 
preclinical ( e.g., molecular biology, cell culture, animal models) or clinical 
( e.g., human drug or vaccine efficacy trials). The preclinical research goal in 
animal experimentation is to generate candidate drugs, bio-medical technol­
ogy or devices and diagnostic tests to evaluate downstream for clinical test­
ing and possibly commercialization, a laboratory-to-patient process called 
translation. Preclinical research also entails toxicity testing of drugs, vaccines, 
chemicals, cosmetics, and other consumer products, usually in mice and dogs. 
Veterinary biomedical animal research is structured essentially the same as its 
human counterpart albeit on a much smaller scale. The desired outcome of 
preclinical research, mostly performed by government and academia, are sci­
entific papers, the currency ( along with grant funds) of research success. The 
desired outcome of applied research, mostly performed by biotechnology and 
pharmaceutical firms, are patented biomedical products that reflect successful 
translation and new revenue streams. Public acceptance of animal research, 
especially if invasive and painful, is contingent on substantial human benefits 
andfiscalaccountability. Unfortunately, taxpayers often support animal research 
under the false hype of "breakthrough" animal model-based medical progress. 
Most preclinical research is publicly funded. The us National Institutes of 
Health (NIH), the world's largest biomedical research organization with a 2019 
budget of us$39.2 billion, emphasizes infectious diseases and oncology (NIH, 
2019 ). The biotechnology and pharmaceutical sectors favor product develop­
ment and commercialization ( e.g., bio-engineered drugs, vaccines and clinical 
trials for cancer, analgesics, anti-diabetic drugs, and some rare diseases). The 
public sector generally relies more on animals than the private sector. How­
ever, the private sector depends indirectly on publicly funded animal research 
as a pipeline for candidate drugs or technologies to convert into marketable 
biomedical products (Dorsey et al., 2009; Moses et al., 2015). 
Tax-supported animal research and testing is conducted or sponsored by 
several us agencies, especially the NIH. Federal laws mandate animal testing 
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of pharmaceuticals, vaccines, and other chemicals to assess their safety and 
efficacy. The Environmental Protection Agency and the Food and Drug Ad­
ministration (FDA) are appropriated vast funds for animal testing. Other us 
agencies that require and/or conduct animal testing include the Department 
of Agriculture (USDA), the Consumer Product Safety Commission, the Depart­
ment of Defense, the National Institute of Environmental Health Sciences, 
and the Department of Transportation. The private sector has decreased ani­
mal testing in some areas, especially in pharmaceuticals ( due to high cost and 
animal model failure) and in cosmetics ( due to consumer pressure). However, 
millions of animals are still used annually by private industry for internal or 
regulatory safety and efficacy testing of agrochemicals, vaccines and other bio­
logics, and chemicals in consumer products (61.8%; us$71 billion). Private in­
dustry is followed by the us government (31.5%; us$45 billion) nonprofits and 
charities (3.8%; us$4.4 billion), and academia (3.0%; us$3.5 billion). About 
us$56,4 billion (49°/o) is spent on preclinical research, with the NIH providing 
most funding. About 47°/o of preclinical research uses animals, of which 51% 
to 89% is flawed. Thus, us$14 billion to us$25 billion (g million to 15 million 
out of 17 million laboratory animals) of us animal research is wasted (Freed­
man, Cockburn and Simcoe, 201s; Moses et al., 201s; National Anti-Vivisection 
Society, 2018). 
2.1 Many Animals 
Precise animal numbers utilized in us biomedical research are unknown be­
cause the large majority ( at least 95%) are exempt from the monitoring, care, 
and reporting requirements of the USDA's Animal Welfare Act (AwA). Mice, 
rats, birds, and fish are exempt. As a result, it is impossible to know how many 
mice and rats are used each year for research in the us, for what purposes, 
and the pain and/ or distress these animals experience because this data is not 
gathered or reported (American Anti-Vivisection Society, 2017). The USDA re­
ported 820,812 AWA-covered animal species used for research, testing, teach­
ing, and experimentation in 2016. About 40% of these animals were reported 
to be subjected to painful procedures, some with and some without anesthe­
sia or analgesia (USDA, 2017). However, this USDA AWA data (animal numbers, 
species, painful procedures, etc.) is facility self-reported and thus unverified. 
It is estimated that roughly 95% of the animals used in us laboratories are 
mice and rats. Assuming relative species use comparability of European Union 
data on vertebrate animals (i.e., mice, rats, birds, fish, and all cold-blooded 
animals), and an AWA non-exempt research animal population of 821,000, 
about 16 million mice are used annually. However, the estimated us research 
mouse population varies between 10 million and 100 million animals, many 
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genetically engineered (Guarino, 2015). Mouse numbers are growing rapidly 
(Goodman, Chandna and Roe, 2015). Extrapolation from Goodman, Chandna 
and Roe's study estimates the us research mouse population at 86 million. 
2.2 The Biomedical Industrial Complex 
The biomedical industrial complex is an international multi-billion-dollar 
business. Animal experimentation in the biomedical industrial complex ( BI c) 
is pervasive, secretive, profitable, and government-sanctioned. The term "in­
dustrial complex" is from the famous and prescient 1961 farewell speech by 
us President Dwight Eisenhower to "beware the military industrial complex", 
the semi-opaque, complicated "dark state" network of relationships between 
governments, the armed forces and the corporate military/security sector 
that supplies them. Like the military industrial complex, the biomedical in­
dustrial complex is an impenetrable, taxpayer-money driven eco-system, 
where the stated bio-medical and public health missions are sometimes sub­
servient to more self-serving ones ( Orzechowski, 2012 ). This does not impugn 
or discredit most animal researchers, who usually have good, if misguided, 
intentions. 
There are innumerable inter-dependent BIC beneficiaries. These include 
millions of investigators ( salaries, prestige), thousands of universities and 
foundations ( overhead, patents, jobs), hundreds of funding organizations 
(jobs, power), numerous biotechnology and pharmaceutical corporations 
(jobs, profits, patents, products) and venture capitalists (return on investment, 
ROI). Moreover, there is a vast subtler army of allied industries ( e.g., equip­
ment, reagent and animal suppliers, consultants, bureaucrats, veterinarians, 
regulators, and publishers). 
Like all taxpayer subsidized enterprises affiliated with human medicine, 
prices for products and services are highly inflated. Animal suppliers breed 
animals, from genetically engineered mice to monkeys, to satisfy researcher 
demands. A New Zealand white rabbit can cost us$350, a monkey us$8,ooo. 
In 2010, the Jackson Laboratory sold 2.9 million mice for a revenue of us$98.7 
million. Suppliers of feed, cages, and equipment have profitable businesses. A 
mouse treadmill may cost us$10,ooo. The us scientific publishing industry gen­
erates us$10 billion in annual revenue Qarvis and Williams, 2016). Biomedical 
research, with or without animals, is particularly lucrative for us universities 
who charge overhead ( facilities and administrative fees) on every research dol­
lar, typically at a 50% rate. About 80% (us$29.8 billion/year) of NI H's us$37.3 
billion annual funding is awarded to universities and research institutes as ex­
tramural competitive grants. Academic "administrative costs" consume one in 
three research grant dollars, approximately us$9.3 billion ( one-fourth) of the 
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entire NIH budget. Overhead primarily pays high university executive salaries 
and building depreciation costs and only marginally supports research and in­
vestigators. By comparison, typical overhead ( fixed costs) for a private us busi­
ness is approximately 23% of sales, salaries, and benefits, inclusive. 
3 The Failure of the Animal Model Paradigm in Biomedical Research 
The problem is that it [ animal research] hasn't worked, and it's time we 
stopped dancing around the problem[ ... ] We need to refocus and adapt 
new methodologies for use in humans to understand disease biology in 
humans [ ... ] You've lost the debate if you lose sight of the taxpayers and 
the patients. 
ZERHOUNI, former head of the us NIH, in McManus, 2013 
The cornerstone of modem biomedical investigation is animal experimen­
tation, but this practice is in the midst of an existential crisis. Up to 88% of 
preclinical biomedical experiments, especially those involving animals, are in­
valid, i.e. derived candidate drugs or vaccines are clinically ineffective or toxic 
(Freedman et al., 2015; Bock, 2016). This results from poor experimental practic­
es intertwined with the abject failure of synthetic disease in animals, from mice 
to chimpanzees, to serve as more than skin-deep human disease surrogates. 
Animal research has always been ethically contested, but there is now indis­
putable evidence of animal model failure to recapitulate human disease and pro­
vide clinical value (Pound and Blaug, 2016). Public support for animal research 
is dropping. From 2009 to 2014, Americans opposing animal use in scientific re­
search increased from 43°/o to 50% (Pew Research Center, 2015). Failed animal 
models are the root cause of disappointing and diminishing returns on biomedi­
cal investments. Poorly designed preclinical animal studies lead to downstream 
expensive but fruitless clinical trials, exposing people to false hopes, potentially 
harmful drugs, or withheld beneficial treatments. Poorly conducted studies pro­
duce unreliable findings and suffering in millions of animals, nullifying the so­
cial and moral justification oflaboratory animal use (Pound and Bracken, 2014 ). 
4 Failure and Waste in Preclinical Animal Research 
4.1 Of Mice Not Men: Animals Are Not People 
Hundreds of thousands of peer-reviewed publications are based on the as­
sumption that human-animal similarities enable knowledge from "animal 
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models" to be extrapolated to people. The belief is entrenched in scientific 
funding agencies and animal experimentalists. However, even if animal re­
search is conducted faultlessly, animal models have limited success in pre­
dicting human clinical outcomes because of inherent evolutionary, genomic, 
epi-genomic, physiological, and other human-animal differences. Human dis­
eases are artificially induced in animals but fail to reproduce the complexity of 
human ailments. Animal models are typically generated through genetic ma­
nipulation, surgical intervention, or injection of foreign substances, produc­
ing ailments with signs similar to a human disease. A common current mouse 
cancer model harvests human tumor cells, grows them in a petri dish and then 
transplants tumor tissue beneath the skin of immuno-compromised mice, 
so that the mice avatars cannot reject the implanted tumors. These so-called 
patient-derived xenografts are then exposed to drugs whose killing efficiency 
and toxicity profiles are extrapolated to treat "personalized" human cancers. 
The cancer research community published an extraordinary 361,693 experi­
mental studies and journal papers according to a PubMed database search I 
conducted on 8 August 2018 using the terms "Mice" and "Cancer". PubMed was 
unable to identify how many successful anti-cancer mouse drugs became FDA­
approved for human use but that number is certainly miniscule. Billions oflost 
dollars clearly show that mice as human disease surrogates are no more analo­
gous than artificially flavored grape drink is to fine French wine. The chimpan­
zee, who shares 99% of its DNA sequence with humans and should best predict 
human outcomes, has largely failed as an animal model, certainly in dozens of 
HIV vaccine trials over the past three decades (Bailey, 2008). A 1% DNA differ­
ence apparently outweighs a 99% similarity. 
5 Irreproducibility 
Science has two aims: to be reproducible ( confirmatory) and to contribute to 
cumulative knowledge ( discovery). Confirmatory science has higher value be­
cause it defines scientific truth, i.e. the non-repeatable is false. An estimated 
51% to 89% of preclinical animal research (us$13.3 billion to us$23 billion) is 
unreliable ( see Table 10.1 ). 
About 1.5 million biomedical scientific papers are published per year. 
Irreproducible but published animal research constitutes severe literature pol­
lution, leading other researchers to follow false leads, amplifying waste (see 
Figure 10.1 ). 
Some cogent and expensive examples of non-repeatable animal experi­
ments are shown in Table 10.2. 
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2 
Downloaded from Brill.com11 /11 /2019 09:57:0BPM 
via free access 
250 
TABLE IO.I Annual us biomedical and agricultural R&D 
investment and estimated wasted animal research monies 
Source Total research Total basic 
investment: basic, or preclini­








Biomedical-basic/preclinical and applied/clinicala 
All 
us$124 billion us$56 billion us$26 billion 
(100%) 
Industry us$71 billion us$34.8 us$16-4 billiond 
(61.8%) billion 
Government 
us$45 billion us$22 billion us$10.4 billion 
(31.5%) 
Non-profits 
us$4.4 billion us$2.2 billion us$1.1 billion 
(3.8%) 
and charities 
Academia us$3.5 billion us$1.7 billion us$8oo million 
(3D/o) 
Animal agriculture-basic and appliedc 
All us$1.4 billion us$686 us$686 million 
(100%) millione 
Industry us$500 million us$245 us$245 million 
(36%) million 
Government us$goo million us$441 us$441million 
(64°/o) million 
All 2 o 1 7 biomedical and agricultural animal research 
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Source Total research Total basic Total animal Wasted 
investment: basic, or preclini- ( assume 4 7°/o money due to 
applied, preclini- cal ( assume of preclinical)b flawed animal 
cal, 49°/oof research 
and clinical total)a (assume51% 
to 89% failure 
rate)8 
Industry us$71.5 billion us$35 billion us$16.6 billion us$8.5-
us$14.8 
billion 
Government us$45.9 billion us$22.4 billion us$10.5 billion us$5.3-us$9.3 
a Freedman et al., 2015 
b National Anti-Vivisection Society, 2018 
c Clancy, Fugile and Heisey, 2016 
billion 
d Probably an overestimate, as industry has a downstream clinical research focus and relies 
much less on upstream animal research than government or academia. 
e Since animal models are rarely used or needed in agricultural animal research, total basic 
research and total animal research dollars are assumed to be the same. 
The most alarming exemplar of irreproducibility is a 2012 Amgen study that 
reproduced key findings in only six of 53 ( n % ) landmark preclinical cancer 
papers, mostly from mouse models, published in premier scientific journals 
(Begley and Ellis, 2012 ). NIH director Francis Collins recently wrote, "A growing 
chorus of concern, from scientists and laypeople, contends that the complex 
system for ensuring the reproducibility of biomedical research is failing and 
is in need of restructuring [ ... ] Preclinical research, especially work that uses 
animal models, seems to be the area that is cu"ently most susceptible to repro­
ducibility issues" ( emphasis added, Collins and Tabak, 2014 ). Why do we contin­
ue to spend so much on flawed animal models that lack validity, resilience, and 
repeatability? 
6 Non-publishable Research and Publication Bias 
A hypothesized treatment in an animal model may be ineffective or toxic, a 
"failure" considered a "negative result". Scientists do not want to submit, and 
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Findings published but 
irreproducible and unsound 
Pollution ofbio-medical 
literature 
FI GURE 1 0 . 1  The animal model of  human disease as  a major driver of  wasted 
money and translational failure in biomedical research. 
journals do not want to publish negative findings because they lack the prestige 
of novel discoveries. This leads to unnecessary repetition of failed (unknown) 
research, amplifying wasted money. Published animal trials overestimate by 
30% the likelihood of treatment success because of "missing" unpublished 
negative findings (Sena et al., 2010 ). 
Unpublished or unpublishable results bias the biomedical literature, fa­
voring positive over negative findings and leading to duplicate studies that 
unnecessarily endanger animal and human subjects and waste resources. 
Clinical trials funded by NIH (almost exclusively based on the false animal-as­
human paradigm) and registered within ClinicalTrials.gov ( clinicaltrials.gov), 
an NIH-run trial registry and results database, showed that fewer than half 
of 635 NIH funded clinical trials between 2005 and 2008 were published in a 
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TABLE 10 . 2  Examples of non-repeatable animal experiments 
Research field Repeatability Estimated wasted Reference 
failure money 
Drug discov- Bayer reports 43 us$67 milliona Mullard, 20 1 1 ;  Beg-
ery: Cancer, of 67 (65%) new ley and Ellis, 2 0 1 2  
women's health, drug targets failed 
cardiovascular to repeat academic 
journal findings. 
Drug discovery: 50% of published Many millions Osherovich, 20 1 1  
All biomedical academic studies 
disciplines in top-tier journals 
cannot be repeated 
with same conclu-
sions by industrial 
labs. 
Drug discovery: Amgen researcher us$53 milliona Begley and Ellis, 
Cancer unable to reproduce 20 1 2  
the findings in 4 7 of 
53  (89%) Landmark 
cancer papers from 
top journals. 
a Cost to repeat preclinical work in industrial labs varies from us$500,ooo to us$2 million per 
compound and three to 24 months. I used a value of us$1 million per drug target (see Freed­
man, Cockburn and Simcoe, 2015). 
peer reviewed biomedical journal within 30 months of trial completion. Fur­
thermore, those that were published omitted key, usually detrimental, details 
(Ross et al., 2012) .  A 2016 study of 4347 interventional clinical trials across 
51 us academic medical centers reported dissemination of results within 24 
months of completion ranging from 16.2% to 55.3%. This occurred in spite 
of a 2008 (unenforced) federal law requiring reporting of clinical trial results 
within 12 months of completion or termination with a (never applied) $10,000 
per day fine for non-compliance (Chen et al., 2016) .  My current home insti­
tution, the University of Nebraska, is the most flagrant violator of clinical 
trial reporting among academic institutions, disclosing less than 20% of clini­
cal trial findings from 2015 to 2017 (Pillar and Bronshtein, 2018) .  En toto, the 
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non-transparent delayed or non-reporting of human clinical trials represents 
the dual wasteful and unethical suffering of many thousands of laboratory 
animals, the compromised safety and squandered sacrifice of thousands of 
participant human subjects and a total disregard for public accountability to 
us taxpayers. 
7 Failure to Translate: Downstream Human Clinical Consequences 
of Flawed Animal Research 
The history of cancer research has been a history of curing cancer in the 
mouse. We have cured mice of cancer for decades and it simply didn't 
work in humans. We need to acknowledge the fact that use of animals 
will not make us better scientists, but bitter scientists. 
RICHARD KLAUSNER, former director of the us National Cancer Institute, 1998, in 
MANDAL and PARIJA, 2013 
As the above quote attests, animal model failure has been well known for 
decades at the highest levels. Animal experiments have contributed to 
understanding mechanisms of disease and normal animal physiology and bio­
chemistry. However, their record in predicting effectiveness, toxicity of treat­
ment, or preventive strategies in human trials is dismal. In fact, clinical trials 
are essential precisely because animal studies do not predict with sufficient 
certainty what will happen in people (van der Worp et al., 2010 ). The pharma­
ceutical industry bemoans the near empty pipeline over the past 30 years of 
new drugs that enter and survive the clinical trial gauntlet to gain FDA approv­
al Serious biases in animal studies makes it nearly impossible to rely on animal 
data to predict whether or not an intervention will be toxic or have a favorable 
clinical benefit-risk ratio in humans (Ioannidis, 2012). Excessive translational 
risk occurs even though there has never been more public and private money, 
trained researchers, and better infrastructure, facilities, and biotechnological 
tools ( e.g., "humanized" mice) than at present. Nearly all candidate drugs de­
rived from preclinical research, entailing immense expenditures and use of 
animal models in which the drugs work well against artificially-induced dis­
ease, fail in human trials (Kaur, Sidhu and Singh, 2016). Well-known examples 
of animal model-to-human clinical failure, costing billions of public and pri­
vate dollars, are shown in Table 10.3. 
Drivers of translation failure include: 
- Irreproducibility: For decades, the pharmaceutical industry has internally 
replicated preclinical research findings, published or otherwise, as standard 
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TABLE I0 . 3  Examples of non-translatable clinical science based on laboratory animal 
research, mostly mouse models. The drugs or other interventions "worked" (non­
toxic, clinically effective) in animal models but were abandoned for use in people 
due to toxicity or lack of therapeutic efficacy 
Research field Repeatability failure 
Type 1 diabetes All 1 9 5  methods that 
prevented or delayed 
development of type 1 
diabetes in mice failed in 
people. 
Human im- 30-40 vaccines in approx. 
mune-deficien- go clinical trials, involv-
cy virus (mv): ing more than 20,000 
pre-clinical, human volunteers, failed; 
and Phase I, I I  all vaccines worked in 
and I I I  vaccine non-human primates, 
trials especially chimpanzees 
injected with HIV; one 
vaccine increased human 
HIV risk. 
Alzheimer's dis- 300 different interven-
ease: preclinical tions reported effective 
in mice, clinical in the amyloid precursor 
trials in people mouse model; none effec-
tive in human trials. Of 
1 ,200 clinical trials, only 
5 drugs approved, which 
treat symptoms but not 
disease progression. 
lschemic stroke Two of 500 neuroprotec-
tive interventions against 
stroke successful in hu-
man clinical trials; one of 
the two beneficial drugs 
was aspirin. 
Estimated wasted Reference 
money 
Billions Roep, Atkinson 
and Herrath, 
2004 
Billions; not one Bailey, 2008 
HIV vaccine FDA-
approved after 30 
years 
Billions Zahs and Ashe 
20 10; Cavana-
ugh, Pippin and 
Barnard, 20 1 4  
Billions van der Worp 
et al., 20 10  
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TABLE 1 0 . 3  Examples of non-translatable clinical science based on laboratory animal 
research, mostly mouse models. The drugs or other interventions "worked" (non­
toxic, clinically effective) in animal models but were abandoned for use in people 
due to toxicity or lack of therapeutic efficacy (cont. ) 
Research field Repeatability failure 
Inflammation 1 50 clinical trials that 
and sepsis tested candidate agents 
intended to block the 
inflammatory response all 
worked in mice; all failed 
in critically ill patients. 
Amyotrophic 1 oo potential drugs in 
lateral sclerosis established animal models, 
(ALS )  of which eight entered clini-
cal trials with thousands 
of people, failed. Clinical 
trials of 24 compounds in 
5 1  studies of 1 3,000 ALS 
patients, found 1 beneficial 
compound. 




Seok et al., 20 1 3  
Perrin, 20 14; Petrov 
et al., 20 1 7  
operating procedure to validate drug targets and initiate internal drug dis­
covery. Non-repeatable results have been disappointing and expensive (see 
Table 10.2 ). The pharmaceutical industry has heavily divested and decreased 
reliance on animals because each translational failure causes significant 
losses of invested capital. European drug companies decreased animal use 
by 25°/o from 2005 to 2008 (Pound and Bracken, 2014) . 
False positive animal model success: Industry researchers must give up when 
a drug is poorly absorbed, unsafe, or does not work. Only five in 5,000 com­
pounds that enter preclinical testing make it to human testing. Only one of 
the five is safe and effective enough to be marketed (FDA, 2017). More than 
go% of promising new compounds fail when tested in humans because 
they are ineffective or toxic, even though each drug performed well in prior 
multi-species animal tests. 
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- False negative toxicity (iatro-epidemics): Severe unintended human harms 
and billions of dollars in damages occur when FDA-approved drugs are 
non-toxic in laboratory animals but cause serious, sometimes fatal iatro­
( medically caused) epidemics after marketplace entry. These adverse drug 
reactions may cause 100,000 us deaths annually, although this is likely a 
highly inflated number (Lazarou, Pomeranz and Corey, 1998). The FDA 
Adverse Events Reporting System (FAERS) is a computerized information 
database designed to support the agency's post-marketing safety surveil­
lance program for all approved drug and therapeutic biologic products. The 
FAE RS contains almost 16 million reports of adverse events and reflects data 
from 1969 to 20181 suggesting limitations to the validity of animal drug or 
biologics toxicity screening (FDA, 2018). For example: 
- The arthritis drug rofecoxib (Vioxx) was safe in eight studies in African 
green monkeys and five other animal species but caused 140,000 heart at­
tacks and 60,000 to 100,000 deaths before withdrawal in 2004. Merck paid 
us$950 million to settle damages in 2011 (Pippin, 2012). 
- Analysis of 780 chemical agents listed in a cancer database found the 
positive predictivity of animal bioassays, for a definite or probable hu­
man carcinogen, to be 20% (Knight, 2007 ). In addition to risking human 
welfare from the low predictability of animal bioassays, each assay re­
quires up to millions of dollars and years to execute (Akhtar, 2015). 
- The diet drug, fen-phen (fenfluramine-phentermine), worked well as 
an appetite suppressant in rats without toxicity. However, this popular 
drug damaged heart valves and caused pulmonary hypertension in some 
people in the 1990s. The FDA withdrew it in 1997. The drug's maker settled 
damage claims for us$3.75 billion (Kolata, 1997; Morrow, 1999). 
- False positive drug toxicity: Just as ineffective and dangerous drugs are ap­
proved based on erroneous safety in animals, useful drugs may be toxic in 
animals but safe for people. Aspirin was patented in 1900, decades before 
mandated animal testing. When later evaluated, aspirin produced birth 
defects in mice, rats, guinea pigs, rabbits, cats, dogs, sheep, and monkeys. 
Post-approval toxicity of penicillin (killed guinea pigs) and tamoxifen (liver 
cancer in rats) was absent in people. If the animal toxicity were known, these 
safe drugs would unlikely be on the market today (Akhtar, 2015). 
- Costs of failed clinical trials: Clinical human research relies on and extends 
preclinical animal research. Unsound animal research leads to precarious 
clinical research outcomes. The FDA drug approval process is stringent and 
tightly controlled and consists of four phases (Phase I to Phase 1v). Phase 1 :  
Is the drug safe in healthy people?; Phase I I :  Does the drug work in patients?; 
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Phase I I I :  Pivotal trials: How does the drug compare to existing treatments?; 
Phase 1v: Post-marketing surveillance: What unknown drug effects (good or 
bad) happen? Only one in 5000 to 10,000 new chemical compounds derived 
from preclinical testing proceed to Phase I (Akhtar, 2015). Phase transition 
success rates are: Phase I to Phase 1 1 :  63%; Phase II to Phase 1 1 1 :  31%; Phase 
1 1 1  to new drug approval: 85%. The overall success rate from Phase I to FDA­
approval is 9.6% (Batelle, 2015). 
The immense attrition of drugs entering human clinical trials has made big 
pharma cautious, even skeptical, of preclinical animal research. In 2013, the 
average time and cost to develop a new drug was 10 years and us$2.6 billion 
(Batelle, 2015). Candidate drugs that fail anywhere in the clinical trial process, 
prior to FDA-approval, still lose millions of dollars. Drug development losses 
are recouped as higher prices for pharmaceuticals already on the market. 
Promising preclinical animal studies that require extensive time, labor, and 
money rarely translate into successful human therapies. The overwhelming 
preclinical tendency to use animal models, in spite of their near universal 
translation failure, invokes the "law of the hammer", a cognitive bias involv­
ing over-reliance on a familiar tool (Kaplan, 1964). Abraham Maslow (1966) 
said, "I suppose it is tempting, if the only tool you have is a hammer, to treat 
everything as if it were a nail". The laboratory mouse is certainly a worn-out 
bio-hammer. 
8 Animal Agriculture Research: Less Money, Fewer Animals, but 
Great Waste All the Same 
According to the USDA, in 2016, approximately 80,000 farm animals (pigs, 
sheep, goats, and cattle) were used in animal testing or biomedical research. 
This excludes federal government owned agricultural-research animals who 
are AWA exempt (approximately 50,000 animals). About us$1.4 billion was 
spent on us agricultural animal research in 2016, including us$900 million in 
public funds (mostly USDA) and us$500 million by private industry (Clancy, 
Fuglie and Heisey, 2016) (see Table 10.1). Animal agriculture research has ap­
proximately 1% of the budget and uses approximately o.8% of the animals 
used in biomedical research. Since experiments are performed directly on the 
target livestock species, animal research in agriculture has the distinct advan­
tage of not relying on animal models. 
8.1 The Animal Agriculture Industrial Complex 
Animal agricultural research is a cog in the large industrial agri-business ecosys­
tem. It directly and indirectly supports an entourage of scientists, government 
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agencies, livestock commodity groups, lobbyists, and the animal health, feed 
and other allied industries (Twine, 2012 ). The dominant raison d'etre of live­
stock research is to benefit people via support of the industrial ("factory farm" 
or "prison") paradigm, i.e. intensively managed and densely confined pigs, 
feedlot beef cattle, dairy cattle, and poultry (Imhoff, 2010 ). There are three 
common aims: 
- To optimize so called production efficiency of meat, milk and eggs i.e. generate 
the greatest output with the fewest inputs. Three tools accomplish this: ge­
netic selection, feed efficiency and animal health, writ large, including growth 
promoting drugs, disease suppressing antibiotics and numerous vaccines. 
To maximize consumption of animal agriculture products. 
To address unintended consequences of industrial animal agriculture ( e.g., 
food safety risk, zoonotic pathogens, antibiotic resistance, and pollution 
from animal wastes). 
g Case Studies in Wasted Money from Animal Research 
The Mad Cow Disease iatro-pandemic and new variant Creutzfeldt-Jakob 
Disease (nvCJD ): The best feed for cows ... is cows! 
"The road to hell is paved with good intentions" 
Saint Bernard of CLAIRVAUX, 1150 
Because feed is the greatest expense in raising livestock ( 65%-75°/o of total 
cost), there is an ongoing quest to lower feed costs. A dominant research goal is 
to increase feed efficiency (feed inputs/outputs of growth, eggs or milk). Feed 
efficiency research focuses on: ( 1) drugs (hormones and antibiotics); ( 2) genetic 
selection; (3) better nutrition; and (4) low cost "waste products" as feedstuffs. 
While com and soybeans are mainstays in us industrialized livestock ra­
tions, less savory ingredients also become animal feeds, especially to meet 
expensive protein needs. Only 60% of a slaughtered cow is edible (i.e. suit­
able as human food). The remaining "inedible" 40% (including hides, bones, 
entrails, lungs, spleens, hooves, fat and gristle, and fetuses, among others), 
known euphemistically as "by-products", are not permitted to be used as 
human food. They can, however, be used in livestock and poultry feeds and pet 
foods. Rendering plants transform slaughter by-products and animals that are 
unsuitable for human consumption into animal feed products using grinding, 
cooking, and pressing processes. Livestock are fed rendered animal fat and pro­
tein from slaughtered food animals and their wastes, including chicken feath­
ers, egg shells, poultry litter (bedding and feces), blood, hair, bone marrow, pig 
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manure, and rumen ingesta. So called "4D" animals ( dead, dying, diseased, 
disabled) also become livestock feed and pet foods. Cost driven same-species 
feeding ( cannibalism) is common and industry-supported in livestock and 
poultry in most countries (Denton et al., 2005). 
Meat and bone meal (MEM,  dried and ground), also known as "animal flour", 
was a small-scale livestock feed for much of the twentieth century. The Ag­
ricultural Research Service, the internal USDA research arm, studied feeding 
bovine MEM to dairy cattle in the 1960s (Brundage and Sweetman, 1963). How­
ever, commercial rendering, industry-sponsored research at the University of 
Nebraska-Lincoln, in the early 1980s, discovered the "by-pass protein effect" 
when cattle are fed high protein MEM from dead cattle (Rampton and Stauber, 
1997). Proteins from rendered bovine MEM,  unlike plant proteins, withstand 
rumen microbial digestion and are delivered intact to the small intestine, max­
imizing growth and lactation in high-yield dairy cattle. Additional University­
sponsored research confirmed the MEM by-pass protein effect, resulting in 
many peer-reviewed papers ( e.g., Stock et al., 1981; Santos et al., 1998). It should 
be no surprise that rumen microbes, evolutionarily designed over millions of 
years to digest forage, are unable to digest MEM,  completely foreign nutrients. 
By analogy, humans would have a difficult time digesting sawdust. By the mid-
198os, MEM bypass protein was widely accepted, especially in Western Europe, 
as a dairy cattle protein source. MEM use in animal feed was heavily dependent 
on its price relative to the price of alternative ingredients ( e.g., soybeans) with 
similar nutrient values. 
However, this anti-nature Faustian bargain of high milk production in ex­
change for cannibalism resulted, starting in the mid-198os, in the bovine spon­
giform encephalopathy (ESE, "Mad Cow") pandemic. This new fatal prion 
(infectious protein) disease spread to cattle eating prion-contaminated bovine 
MEM, amplified by "recycling" rendered cattle that died of ESE into even more 
prion-contaminated MEM. In Britain, 185,000 live cattle were ESE-infected, 
4-4 million were slaughtered during the 1986-1998 eradication program, and 
perhaps a million ESE-infected cattle entered the human food chain. Cattle 
in 30 countries were infected. Thousands of European dairy farmers lost their 
livelihoods (Brown et al., 2001). Since the 1996 discovery that ESE was trans­
missible to humans from eating prion-contaminated beef, at least 231 persons 
in 13 countries died from new variant Creutzfeldt-Jakob Disease (nvCJD), the 
zoonotic manifestation of ESE (Maheshwari et al., 2015). Since the first us ESE 
case in 2003, the us cattle industry has forfeited billions of dollars from lost 
exports, decreased product value, lower consumption, and new regulatory bur­
dens. This tragic MEM cow cannibalism story shows that "production efficien­
cy" research can have incredible negative sequelae and vividly demonstrates 
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the myth of so-called peer-reviewed sound science. Unfortunately, the BSE 
experience has not completely tempered the feeding of animal protein to 
herbivores. 
9.1 Livestock Research at the USDA us Meat Animal Research Center ( us 
MARC ) 
I worked at the USDA Agricultural Research Service of the Meat Animal Re­
search Center (MARC) in Nebraska from 1988 to 2014 in various veterinary 
clinical and research positions for the USDA and the University of Nebraska­
Lincoln (UNL ). The USDA and UNL jointly operate MARC , the world's largest 
livestock research center. It has a federal appropriation of us$22 million per 
year, plus approximately us$5 million in annual revenue from livestock sales, 
a cumulative us$1.3 billion budget over the half century it has existed. MARC 
is essentially a 55 square mile (14,200 hectare) ranch surrounding a research 
campus. Each year, MARC 's 61800 brood cows raise 6,000 calves, 600 sows pro­
duce 14,000 piglets, and 2,800 ewes birth 5,000 lambs; 35,000 animals in total. 
Almost all Agricultural Research Service livestock and meat research is direct­
ed toward helping large producers and processors. In particular, much current 
Agricultural Research Service research addresses the untended negative conse­
quences of industrial animal agriculture, for example food safety risk, zoonotic 
pathogens, drug residues, antibiotic resistance and pollution from animal 
wastes. 
A former MARC Director told me directly that since an executive branch 
agency (such as the Agricultural Research Service) cannot lobby Congress (the 
Hatch Act of 1939 ), he would tell the livestock trade and lobbying associations 
what research MARC wanted to do. These associations would then lobby Con­
gress on MARC 's behalf, often resulting in new funding for MARC , frequently as 
budgetary earmarks. In return, MARC would ( and still does) perform taxpayer­
subsidized research directly addressing pressing priority livestock and meat 
industry concerns. 
Thus, in addition to its multi-million dollar federal research budget, MARC 
performs targeted research on behalf of, or funded by, livestock commod­
ity groups. For example, the National Cattlemen's Beef Association (NCBA), 
a trade association and lobbying group for mostly large us beef producers 
and slaughter processors, has a very close and decades-long association with 
MARC. The NCBA funded at least 52 research projects at MARC between 1999 
and 2017. These included one project in genetic selection, nine in meat quality, 
and 42 in beef safety (zoonotic bacteria and antibiotic resistance). Each NCBA 
proposal typically provides funding of us$100,ooo for one year and does not 
cover MARC labor or equipment costs. Thus, this represents a us$5.2 million 
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NCBA research investment in MARC over 18 years (National Cattlemen's Beef 
Association, 2017). However, since MARC provides "free" labor (~80% of the 
cost of research), this $5.2 million industry "investment" in MARC signifies a 
taxpayer gift of at least $20.8M to the N c BA over 18 years, an impressive return 
in investment. The North American Meat Institute, a meat and poultry trade 
association representing meat packers and processors is also a frequent funder 
of industry research at MARC. 
MARC 's mission is to apply science and technology for red meat production 
efficiency to benefit consumers, producers, and animal agri-business, with a 
genetic selection focus. Among livestock producers, animal scientists, and beef 
geneticists, MARC is a world-famous, NIH-Mayo Clinic equivalent for red meat 
livestock R&D. Like all industrial livestock based-systems, MARC achieves "pro­
duction efficiency" using three tools: 
- Genetic selection: Choose a desirable and heritable production trait ( e.g., 
many offspring; large muscles) and vigorously (hyper) select for this attri­
bute over many generations. 
- Feed efficiency: Maximize via genetic selection and/or experimental low­
cost feeds. For example, in the early 1980s, MARC scientists fed high pH 
cement kiln dust ( a by-product of cement manufacturing) to feedlot steers, 
sheep, and pigs as a calcium feed supplement and to buffer the danger­
ously acidic rumen or stomach pH of animals fed high-energy com ra­
tions (Wheeler et al., 1981; Pond et al., 1982). Cement kiln dust is the fine­
grained, solid, highly alkaline waste removed from cement kiln exhaust 
gas by air pollution control devices. Toxicity led to abandonment of these 
experiments. 
- "Factory farm-acology": Use drugs to improve feed efficiency and promote 
fast lean growth, such as anabolic steroids (hormone implants), antibiot­
ics, ionophores, and beta-agonists (repartitioning agents that convert fat to 
muscle) (Petersen, 2012 ). The cumulative drug effects are rapid growth and 
maximized lean muscle mass. 
As a cogent example of MARC funding of industry research, USDA and UNL 
investigated the growth and "welfare" (body temperature and mobility) ef­
fects of zilpaterol, a beta-agonist growth promotant, on MARC feedlot steers 
(Boyd et al., 2015). Zilpaterol is a failed human asthma drug whose undesirable 
human side effect of turning fat into muscle was a very desirable outcome in 
cattle. This drug is approved for use in livestock in only five countries ( Centner, 
Alvey and Stelzleni, 2014). Zilpaterol was voluntarily removed from the mar­
ket by Merck in 2013 due to serious animal welfare concerns. This zilpaterol 
research at MARC , tri-funded by USDA, UNL and the Nebraska Beef Council, 
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not surprisingly reported no welfare problems in using this fat-to-muscle 
repartitioning agent. Of interest in this MARC feedlot study are: (1) all nine 
authors were livestock scientists; no person with animal or livestock welfare 
training or expertise was part of the study; (2) an unreferenced and invali­
dated meat industry-developed 5-level ordinal lameness scoring metric was 
employed (Tyson mobility scoring, Tyson Foods, Springdale, AK) and; (3) eval­
uators were not blinded as to treatment group, a dominant source of experi­
mental bias. 
I will recount three examples of MARC research principles in action, all with 
animal welfare repercussions and massive waste of taxpayer dollars. 
9.2 Twinner Beef Cattle 
Rationale: Cows usually have one offspring. The natural twinning rate in cattle 
is 1%-2%. Production efficiency would double if cows had twins instead of 
singlets. 
Results: From 1981 until 2011, the twinning rate in a MARC herd rose to ap­
proximately 50% (1.6 calves per cow) via intense genetic selection. 
Problems: (1) It is bio-unnatural for cows to have twins, fighting against mil­
lions of years of evolution favoring singlets; ( 2) Dystocia, C-sections, mas ti tis, 
early calf deaths, and sterile female calves. 
Outcome: The project was abandoned after 30 years and approximately 100 
million tax dollars. There was no market for twinning cows. Most farmers cull 
cows with twins due to the well-known problems described above. A beef ge­
neticist said in 20161 "There are animals in this world that God made to have 
twins or triplets; cows are made to have one" (Simmons, 2016). 
9.3 ''Double muscled" Beef Cattle 
Rationale: Cattle with more muscle mass have greater productivity. Belgium 
blue cattle can have a mutant myostatin gene, causing skeletal muscles to grow 
continuously, producing massive animals. 
Results: MARC scientists co-identified the myostatin gene mutation as caus­
ative for double muscling and developed a test for its genetic selection world­
wide. Production efficiency experiments conducted over many years produced 
cattle with very large muscle mass. 
Problems: Dystocia, low fertility, low stress and heat tolerance, poor calf 
viability. 
Outcome: The project started in 1997 and was abandoned after many years 
and millions of tax dollars. There is no market for these cattle (Elstein and 
Peabody, 2004; Bassett, 2009 ). 
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Rationale: The us commodity sheep industry is becoming extinct. In 2015, 
there were less than 5 million sheep, a 91% decline since 1950. Labor is costly. 
Solution: Increase sheep production efficiency by developing a cross-bred 
fecund breed. This "easy care" sheep has hair ( since us wool has negative eco­
nomic value) and births twins or triplets. Use brutal neo-Darwinian selection 
via hands-off husbandry to select sheep that raise lambs, who require minimal 
labor, feed inputs, and human attention. 
Results: From 2002 to 2017, approximately 1,500 easy care ewes gave birth to 
3,000-5,000 lambs per year. Rather than the usual summer pasture and winter 
shed housing and lambing, "easy care" sheep were kept on isolated pastures 
year-round without shelter or shade. Shepherds were prohibited, by experi­
mental protocol, from intervening to care for ewes or lambs in need. Ewes that 
survived and reared lambs under these heinous conditions were considered 
"successfully genetically selected". 
Problems: Predictably, human-dependent domestic sheep treated like wild 
sheep faired very poorly. Lamb mortality ranged from 10% to 50% per year 
(normal rates are 1%-5%). Over 15 years, 15-20 thousand lambs died (the ex­
pected number was 1,200) from coyote predation, starvation, exposure, aban­
donment, dystocia, and disease. 
Outcome: Like the Twinner cattle, the "easy care" sheep project used in­
tense long-term genetic selection in an anti-nature, poor welfare manner to 
attempt to create a product without commercial demand. The easy ("No") care 
sheep research failed completely, unsurprisingly, to reach its scientific goal 
of a new sheep breed with low labor needs. Over 15 years, the project spent 
approximately 15 million tax dollars. No scientific papers resulted from this 
work. 
These three MARC projects share several commonalities: 
- Intense genetic selection created or attempted to create a livestock product 
no one wanted where production efficiency at all ( animal and taxpayer) costs 
was the focus. 
- Genetics were used as a biological hammer to select for abnormal, exag­
gerated, or unnatural traits that were both costly and harmful to livestock 
well-being. 
- Projects were internally and non-competitively funded for decades with 
millions of tax dollars. 
- MARC livestock, like all federal government-owned agricultural research 
livestock, are AWA-exempt and subject to almost no internal or external ani­
mal welfare oversight which are mandated for other us research animals. 
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The industrial animal agriculture system does not merit research funding 
from the public treasury, as exemplified by the decades of failed and unneces­
sary research and multi-millions of wasted tax dollars at MARC . It is almost 
impossible to justify research support for an unsustainable system that pro­
duces Mad Cow disease, antimicrobial resistance, pollution from livestock 
wastes, food-borne pathogens (e.g., E coli 0157), and horrible livestock and 
poultry welfare. "Cheap" factory-farmed eggs, beef, pork and chicken enabled 
by intensive agricultural animal research are incredibly expensive (Pew Chari­
table Trusts, 2008). 
10 Conclusions 
Publicity is justly commended as a remedy for social and industrial dis­
eases. Sunlight is said to be the best of disinfectants; electric light the 
most efficient policeman. 
LOUIS D. BRANDEIS, 1914 
It is an economic and ethical imperative to reduce wasted money and ani­
mals used in us biomedical and agricultural animal research. These impera­
tives are unlikely to manifest in the current animal research environment due 
to perverse incentives. Complete transparency ( e.g., costing, specific animal 
usage, outcomes, evidence of translational success, mandatory public re­
porting of all government funded research regardless of results) in both the 
public and private domains will likely be the most effective driver of fiscal 
responsibility and refining (minimizing experimental suffering), reducing 
(minimizing animal numbers), and replacing (with non-animal alternatives) 
research animal use. This will require, at a minimum, sustained public pres­
sure, policy and regulatory changes ( e.g., removal of species or institutional 
exemptions from the AWA), adequate resourcing, and enforced (new or old) 
legislation. 
Animal research is losing its immunity from criticism or challenge. How­
ever, it is a multi-billion-dollar industry in which government, academia and 
private business have high financial stakes (Pound and Bracken, 2014). It is 
critical to recognize that wasted money in animal research is only germane 
to laboratory animals and to people excluded from the animal research in­
dustrial complex (i.e., taxpayers, patients, investors, and consumers). To those 
within the animal research ecosystems, there is no waste or cost, only suste­
nance and benefit. This is a major reason why wasteful, unproductive, and even 
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counterproductive use of research animals not only continues but is fiercely 
defended despite obvious limitations and dangers. Supporters of animal re­
search rely on expert opinion ( one of the least valid types of evidence) and 
the occasional translational success story. Opponents have billions of wasted 
dollars, millions of scientific papers, and decades of evidence against their 
continued use. Government sponsored animal experiments may continue be­
cause they are taxpayer-subsidized and incentivized. The pharmaceutical and 
biotechnology industries may reduce laboratory animal use in drug discovery 
and development, because they cannot invest heavily in such an unreliable 
methodology. Unfortunately, scientific precedent, legal liability concerns, and 
regulatory approval mandates will ensure enormous use of laboratory animals 
in the private sector to assess safety of drugs, medical devices, biologics, chem­
icals, and consumer products and to test vaccines (for potency and by batch), 
at least in the near term or until regulatory requirements change. 
Available and emerging non-animal research approaches and technologies 
can provide better return on investment, more valid and valuable findings, and 
better human well-being outcomes and save billions of taxpayer dollars and 
millions of animal lives (D'Urbino, 2016). Goals should include: 
- Abandoning molecular reductionism ( e.g., as manifested in genetically 
modified or "gene knock out" mice). 
- Investigating complex naturally-occurring disease in humans and animals 
instead of artificial and incongruent animal models. 
- Implementing more in vitro (human or animal cell-based assays) and in 
silico ( computer modeling) technologies. 
- Resourcing development, validation, and regulatory acceptance of non­
animal alternatives ( e.g., the Interagency Coordinating Committee on the 
Validation of Alternative Methods, I C CVAM (National Toxicology Program, 
2018)). 
- Defunding public biomedical research that uses animal disease models. 
- Eliminating non-competitive internal government research funding and 
halving extramural grant overhead rates. 
- Discontinuing the failed research focus in agriculture on industrial live­
stock "production efficiency" in favor of humane sustainable agricultural 
research. 
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